Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics

This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.

Leave a Reply